Continuous control of tracheal cuff pressure for VAP prevention: a collaborative meta-analysis of individual participant data by unknown
Nseir et al. Ann. Intensive Care  (2015) 5:43 
DOI 10.1186/s13613-015-0087-3
RESEARCH
Continuous control of tracheal cuff 
pressure for VAP prevention: a collaborative 
meta-analysis of individual participant data
Saad Nseir1,2*, Leonardo Lorente3, Miquel Ferrer4, Anahita Rouzé1, Oswaldo Gonzalez3, Gianluigi Li Bassi4, 
Alain Duhamel2,5 and Antoni Torres4
Abstract 
Background: Underinflation of tracheal cuff is a risk factor for microaspiration of contaminated secretions and sub-
sequent ventilator-associated pneumonia (VAP). The aim of this collaborative meta-analysis of individual participant 
data is to determine the impact of continuous control of Pcuff on the incidence of VAP.
Methods: Studies were identified by searching PubMed and references of relevant articles. Data from 3 prospective 
controlled trials (two randomized and one quasi-randomized), which evaluated the impact of continuous control of 
Pcuff on the incidence of VAP, were obtained and pooled together. Three different devices were used to continuously 
control Pcuff. VAP was diagnosed using clinical, radiologic, and quantitative microbiological criteria. The impact of con-
tinuous control of Pcuff on VAP was assessed by Cox regression analysis, stratified on trial.
Results: 263 (48.4 %) patients received continuous control of Pcuff, and 280 (51.5 %) patients received routine control 
of Pcuff using a manometer. 36 (13.6 %) VAP were diagnosed in continuous control group, and 72 (25.7 %) in routine 
care group (HR 0.47, 95 % CI 0.31–0.71, p < 0.001). However, heterogeneity was apparent in continuous control effect 
size across trials (I2 = 58 %, p = 0.085). The number of patients needed to treat to prevent one VAP episode was 8. No 
significant impact of continuous control of Pcuff was found on duration of mechanical ventilation, ICU length of stay, 
or mortality.
Conclusion: Continuous control of Pcuff might be beneficial in reducing the risk for VAP. However, no significant 
impact of continuous control of Pcuff was found on duration of mechanical ventilation, ICU length of stay, or mortality.
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Background
Prevention of ventilator-associated pneumonia (VAP) 
is an important strategy to improve the quality of care 
provided to critically ill patients [1–3]. While VAP-
attributable mortality is still a matter for debate [4], this 
ICU-acquired infection is associated with increased anti-
microbial use and duration of mechanical ventilation [5, 
6]. Important progress has been achieved during the last 
two decades in the understanding of pathophysiology of 
VAP, resulting in improvement in prevention strategies 
and reduced incidence of VAP [7, 8].
Microaspiration of contaminated oropharyngeal and 
gastric secretions is the main mechanism of entry of 
bacteria into the lower respiratory tract [9, 10]. Local 
and general host defenses play an important role in the 
progression from colonization to VAP [11]. The quan-
tity and virulence of bacteria are also important factors 
in this process [12]. Several measures have been studied 
for prevention of microaspiration in intubated critically 
ill patient. These could be classified into enteral nutrition, 
mechanical ventilation, tracheal tube, and patient-related 
factors [13]. With regards to tracheal tube, several recent 
studies investigated how sealing could be improved, 
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in order to avoid microaspiration. Subglottic secretion 
drainage has been shown to significantly reduce VAP 
incidence, antimicrobial use, and duration of mechanical 
ventilation [14, 15]. Other preventive measures related 
to tracheal tube, such as polyurethane cuff and conical 
cuff shape have been suggested. However, a recent ran-
domized controlled multicenter study did not report any 
significant impact of these measures regarding the rate of 
tracheobronchial colonization, or VAP [16].
Underinflation of tracheal cuff (<20 cmH2O) is a well-
known risk factor for microaspiration and VAP [17]. 
Therefore, it is recommended to adjust cuff pressure 
(Pcuff) around 25 cmH2O using a manometer, to prevent 
complications related to underinflation and overinfla-
tion of tracheal cuff [18]. However, in spite of routine 
control of Pcuff using a manometer, underinflation and 
overinflation are very common in intubated patients 
[19, 20]. Continuous control of Pcuff has been suggested 
to improve tracheal sealing and to prevent VAP. Three 
prospective trials evaluated the impact of continuous 
control of Pcuff on the incidence of VAP [21–23]. How-
ever, all these studies were performed in single centers 
and reported different results. Therefore, we performed 
this collaborative-pooled meta-analysis to determine the 
impact of continuous control of Pcuff on the incidence of 
VAP in critically ill adult patients.
Methods
We established a collaboration to undertake this meta-
analysis of individual patient data. We included all pro-
spective trials, which evaluated the impact of continuous 
control of Pcuff on the incidence of VAP.
Ethical aspects
The three studies used for this pooled analysis have 
been approved by local institutional regulatory boards. 
Informed consent was obtained from all patients, or from 
their next of kin.
Search for eligible trials
We identified clinical prospective clinical trials that com-
pared the continuous control of Pcuff and routine care 
regarding the incidence of VAP. We searched PubMed 
(from January 1995 through June 2015), using the terms 
“continuous control of tracheal cuff pressure,” “continu-
ous control of endotracheal cuff pressure,” and the term 
“ventilator-associated pneumonia.” We also searched 
references of relevant articles. Studies comparing con-
tinuous control of Pcuff and another intervention versus 
routine care were excluded, because it is impossible to 
determine the exact impact of continuous control of Pcuff 
on VAP rate in these studies.
Outcomes
The primary outcome was the incidence of VAP. Sec-
ondary outcomes included duration of mechanical ven-
tilation, mechanical ventilation-free days, duration of 
antimicrobial treatment, length of ICU stay, and ICU 
mortality.
Collected data
The rationale for choice of factors was based on prior 
association with outcome. At ICU admission: age, acute 
physiology and chronic health evaluation (APACHE) II 
score, sequential organ failure assessment (SOFA) score, 
male gender, cause for ICU admission, type of admis-
sion, diabetes mellitus, chronic obstructive pulmonary 
disease (COPD), chronic heart failure, cirrhosis, chronic 
renal failure, and immunosuppression. During ICU stay: 
SOFA score at randomization, subglottic secretion drain-
age, duration of mechanical ventilation before randomi-
zation, sucralfate, proton-pump inhibitor, or H2 receptor 
antagonist use, reintubation, mean Pcuff, percentage of 
Pcuff measurements  <20 cmH2O, underinflation of Pcuff 
(<20 cmH2O), overinflation of Pcuff (>30 cmH2O), mean 
positive end expiratory pressure (PEEP) level, sedation, 
Ramsay score, head of bed elevation, paralytic agent use, 
red blood cell transfusion, enteral nutrition, ventilator-
associated tracheobronchitis (VAT) [24], and tracheos-
tomy. At VAP diagnosis: polymicrobial VAP and type of 
microorganisms.
VAP definition
VAP was defined as the presence of new or progressive 
pulmonary infiltrate and at least two of the following 
criteria: (a) fever (≥38  °C) or hypothermia (<36  °C), (b) 
leukocytosis (>12 × 109/L) or leukopenia (<3.5 × 109/L), 
and (c) purulent respiratory secretions. Microbiologi-
cal confirmation was required in all patients (positive 
bronchoalveolar lavage ≥104 cfu/mL, or positive tracheal 
aspirate  ≥105 cfu/mL) [25]. Only first episodes of VAP 
diagnosed  >  48  h after starting mechanical ventilation 
were taken into account.
Statistical analysis
Quantitative variables are expressed as mean [±stand-
ard deviation (SD)] in case of Gaussian distribution, or 
median [interquartile range (IQR)] otherwise. Normality 
was examined using histograms and Shapiro–Wilk test. 
Qualitative variables are expressed as numbers (percent-
age). Patient characteristics at ICU admission and dur-
ing ICU stay; and secondary outcomes were compared 
between the two study groups using Student t-test for 
quantitative variables (Mann–Whitney U test was used 
for non-Gaussian distribution) and Chi-square test for 
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qualitative variables (Fisher’s exact was used when the 
expected cell frequency was <5).
The probability of VAP occurrence over time was 
compared between the two study group using a Cox 
proportional hazard model stratified on trial. Hetero-
geneity across trials was examined by formal interac-
tion test and quantified by calculating the I2. Patients 
were censored at the time of death or extubation. We 
performed an exclusion sensitivity analysis to evalu-
ate the contribution of individual studies to the over-
all pooled estimate. A sensitivity analysis excluding 
patients receiving subglottic secretion drainage was also 
performed.
In both groups pooled together, we used a Cox propor-
tional hazard model stratified on trial to identify factors 
associated with the occurrence of VAP. All variables with 
a p value < 0.20 were included into a backward-stepwise 
Cox regression analysis.
Statistical analysis was done at the 2-tailed α level of 
0.05, except tests for the homogeneity in which an α level 
of 0.10 was chosen. Data were analyzed with the SAS 




Among the 30 identified studies, 23 studies were directly 
excluded (reviews 9, duplicates 5, out of scope 5, oth-
ers 4). Among the 7 remaining studies, 2 were excluded 
because Pcuff control was not continuous, and 2 because 
other concomitant preventive measures were used in the 
intervention group (Fig. 1).
Data from 543 patients were obtained from the three 
included trials, representing 99 % of all included patients 
(5 patients were excluded for missing data). Two stud-
ies were randomized controlled and one was quasi-ran-
domized controlled (patients who were admitted to an 
odd-numbered ICU cubicle received continuous control 
of Pcuff, and those admitted to an even-numbered ICU 
cubicle received routine care). Three different devices 
(Mallinckrodt Pressure Control®, VBM Medizintechnik 
GmbH, Sulz am Neckar, Germany; Nosten®, Leved, Saint 
Maur, France; and an electronic artisanal device) were 
used to continuously control Pcuff. Subglottic secretion 
drainage was used in some patients included in one trial. 
All tracheal tubes were polyvinyl chloride (PVC), stand-
ard shape—cuffed. Characteristics of the three studies 
are presented in Table 1.
Patient characteristics
Two hundred and sixty-three (48  %) patients received 
continuous control of Pcuff and 280 (52 %) received rou-
tine care using a manometer. No significant difference 
was found in patient characteristics at ICU admission 
between patients who received continuous control of 
Pcuff, and those who received routine care (Table  2). 
While mean Pcuff was significantly higher in patients 
who received continuous control of Pcuff compared with 
those who received routine care, rate of patients with 
underinflation of Pcuff, with overinflation of Pcuff, and per-
centage of Pcuff measurements <20 cmH2O were signifi-
cantly lower in patients with continuous control of Pcuff 
compared with those who received routine care. Other 
patient characteristics during ICU stay were similar in 
the two groups (Table 3).
Characteristics of VAP patients
One hundred and eight (19.8  %) patients developed at 
least one VAP episode. Early-onset and late-onset pneu-
monia represented 49 and 51 % of VAP episodes, respec-
tively. Duration of mechanical ventilation [5 (2, 10) vs 6 
(3, 10) days, p = 0.323] and percentage of patients with 
early-onset or late-onset VAP (8 vs 12  %, 6 vs 14  %, 
p  =  0.153; respectively) were similar in patients with 
continuous control of Pcuff compared with patients with 
routine care. Ten patients (9 %) had polymicrobial VAP. 
Gram-negative bacteria and MDR bacteria represented 
84 and 36 % of microorganisms responsible for VAP epi-
sodes, respectively. Pseudomonas aeruginosa was the 
most frequently identified microorganism (16  %), fol-
lowed by Staphylococcus aureus (10 %), and Enterobacter 
spp. (10 %) (Table 4).
Impact of continuous control of Pcuff on outcomes
Continuous control of Pcuff was associated with sig-
nificantly reduced incidence of VAP, with a HR of 0.47 
(95  % CI 0.31–0.71) (Fig.  2). However, heterogeneity in 
continuous control effect size across trial was apparent 
(I2 = 58 %, p = 0.085). The effect of continuous control 
of Pcuff to reduce the incidence of VAP remained signifi-
cant in exclusion sensitivity analysis, with a lower effect 
after exclusion of the study of Nseir and colleagues (HR 
0.58; 95 % CI 0.37–0.92, p = 0.019). In further sensitivity 
analysis, excluding patients receiving subglottic secretion 
drainage, the effect of continuous control of Pcuff on VAP 
occurrence was not modified with a HR of 0.52 (95 % CI 
0.33–0.79).
In multivariate cox regression analysis, continuous 
control of Pcuff remained significantly associated with 
decreased risk for VAP [HR 0.42, 95  % CI (0.27–0.64), 
p < 0.0001], independently of subglottic secretion drain-
age, chronic renal failure, respiratory, and digestive fail-
ures at ICU admission.
No significant difference was found in VAT rate 
between patients with continuous control of Pcuff and 
patients with routine care [13 of 263 (5  %) patients vs 
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22 of 280 (8 %), p = 0.227]. No significant impact of this 
procedure was found on duration of mechanical venti-
lation, mechanical ventilation-free days, antimicrobial 
treatment, length of ICU stay, or ICU mortality (Table 5).
Safety data and cost‑effectiveness
Similar rates of tracheostomy and reintubation were 
found in patients who received in patients with continu-
ous control of Pcuff compared with patients with rou-
tine care (Table  3). No significant difference was found 
in tracheal ischemic lesions between the two groups 
(n = 96).
The number of patients needed to treat to prevent one 
VAP episode was 8.
Discussion
Our results suggest that continuous control of Pcuff might 
be beneficial in reducing the incidence of VAP. However, 
continuous control of Pcuff had no significant impact on 










Control of Pcuff not 
connuous (n=2) 




Duplicates (n= 5) 
Out of scope (n= 5)
Others (n=4)
Fig. 1 Studies evaluated for inclusion in this analysis
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ventilation, mechanical ventilation-free days, antimicro-
bial treatment, ICU stay, or ICU mortality.
Strengths and limitations
The major strengths of this study are the large number of 
included patients (n = 543) and the collaborative-pooled 
design. The similarity of the trials, including interven-
tion, disease, and study population, provided a strong 
rationale to pool individual patient-level data. How-
ever, some limitations of our study should be acknowl-
edged. First, the number of included studies was small, 
one study was quasi-randomized, and different devices 
were used to continuously control Pcuff in these trials, 
which could probably explain the observed heterogene-
ity in estimates. Nevertheless, percentage of measure-
ments of Pcuff < 20 cmH2O in continuous control of Pcuff 
group was quite similar in the three studies. Other dif-
ferences between the three studies, including the lower 
rate of VAP in control group, and the higher percent-
age of patients with chronic respiratory disorders in 
one study [21] compared with the two others, could also 
explain the high heterogeneity. Second, no significant 
impact of continuous control of Pcuff was found on sec-
ondary outcomes, such as duration of mechanical ven-
tilation, mechanical ventilation-free days, antimicrobial 
treatment, or ICU mortality. This could be explained by 
the fact that a larger study sample is required to dem-
onstrate such an effect. A posteriori calculation, based 
on the results of the current meta-analysis, of number 
of patients required to demonstrate a significant impact 
of continuous control of Pcuff on outcomes indicates that 
348 patients are required to demonstrate a reduction of 
VAP incidence of 12 % (from 26 to 14 %, p = 0.05, power 
80 %), and 1132 patients are required to demonstrate a 
reduction of mechanical ventilation duration of 2  days 
(mean 14 vs 12  days, standard deviation 12, p  =  0.05, 
power 80 %). Previous well-conducted randomized con-
trolled studies aiming at evaluating a preventive meas-
ure of VAP also suffered from this limitation [14, 26, 
27]. For example, several randomized controlled studies 
comparing subglottic secretion drainage to routine care 
demonstrated a significant reduction in VAP rate, but all 
failed to show any significant reduction in mortality rate 
or duration of mechanical ventilation. However, a large 
meta-analysis [15] performed on 2442 patients showed a 
significant reduction in mechanical ventilation duration 
in patients with subglottic secretion drainage compared 
to those with routine care. Third, subglottic secretion 
drainage was used in some patients of one trial, and 
might have influenced the results. However, the rate of 
patients who received subglottic secretion drainage was 
similar in patients who received a continuous control 
of Pcuff and those who received routine care. In addi-
tion, sensitivity analysis excluding patients who received 
subglottic secretion drainage did not modify the protec-
tive effect of continuous control of Pcuff on VAP inci-
dence. Fourth, cost-effectiveness analysis could not be 
performed. However, the number of patients needed 
to treat to prevent one VAP episode was 8. Fifth, the 
safety of continuous control of Pcuff, regarding tracheal 
ischemic lesions, was evaluated in only one study. Sixth, 
the under-reporting of negative results could have biased 
Table 1 Characteristics of studies assessing the impact of continuous control of cuff pressure on the incidence of ventila-
tor-associated pneumonia
Results are %, unless otherwise specified
VAP ventilator-associated pneumonia, CHX chlorhexidine, NS not significant
Valencia et al. [21] Nseir et al. [22] Lorente et al. [23]
Number of included patients 137 122 284
Type of study Randomized controlled Randomized controlled Quasi-randomized controlled
Primary objective VAP Microaspiration VAP
Device Electronic Pneumatic Electronic
Target Pcuff (cmH2O) 25 25 25
Surgical patients 28 0 28
Chronic respiratory disorders 38 27 15
VAP preventive measures
 Oral care CHX 0.12 % X3/days CHX 0.10 % X3/days CHX 0.12 % X3/days
 Semirecumbent position Yes Yes Yes
 Subglottic secretion drainage No No Yes
VAP incidence in control group 15 26 22
Reduction in VAP rate NS 62 51
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our results. However, we have checked the abstract of 
the major international critical care congresses and did 
not find any additional study on the impact of continu-
ous control of Pcuff on VAP incidence.
Explanations for study results
Rello et al. [17] have previously reported that underin-
flation of Pcuff was independently associated with VAP 
in a subgroup of patients without antimicrobial treat-
ment. In addition, one of the three studies included in 
this analysis [22] has investigated the impact of con-
tinuous control of Pcuff on microaspiration of gastric 
content and tracheobronchial colonization. This study 
reported a significant (27  %) reduction of microaspi-
ration of gastric contents, defined as the presence of 
pepsin in  >65  % of tracheal aspirates, in patients who 
received continuous control of Pcuff, compared with 
those who received routine care. Further, a significant 
reduction in bacterial concentration in tracheal aspi-
rates was also observed.
Several studies reported that routine care using a 
manometer was not efficient in continuously controlling 
Pcuff, and that risk factors for underinflation and over-
inflation of tracheal cuff were not modifiable [19, 28, 
29]. Other studies clearly showed the efficiency of some 
devices in continuously controlling Pcuff, suggesting that 
their use might be beneficial in preventing intubation-
related complications [30, 31].
Two randomized studies, excluded from this analysis, 
reported a beneficial effect of continuous control of Pcuff 
on VAP incidence [32, 33]. However, in these studies con-
tinuous control of Pcuff was not the only tested preven-
tive measure. While, low-volume low-pressure cuff was 
used in intervention group, PVC-standard cuff was used 
in routine care group. Therefore, it is impossible to deter-
mine whether the reduced incidence of VAP is related to 
Table 2 Patient characteristics at ICU admission
Data are number (%), or median (IQR); unless otherwise specified
APACHE acute physiology and chronic health evaluation, SOFA sequential organ 
failure assessment
a Some patients had more than one cause for ICU admission
Continuous control of Pcuff
Yes (n = 263) No (n = 280) p value
Age, years, mean ± SD 61 ± 16 63 ± 15 0.141
APACHE II score 18 (13, 23) 18 (13, 23) 0.624
SOFA score 5 (3, 7) 5 (3, 8) 0.424
Male gender 177 (67) 172 (61) 0.181
Direct admission 86 (33) 86 (31) >0.999
Cause for admissiona
 Cardiac surgery 23 (10) 26 (9) 0.944
 Cardiovascular failure 52 (20) 49 (17) 0.569
 Respiratory failure 98 (37) 104 (37) >0.999
 Digestive failure 25 (9) 27 (10) >0.999
 Neurologic failure 48 (18) 52 (18) >0.999
 Others 18 (7) 24 (8) 0.554
Type of admission 0.868
 Surgical 57 (22) 62 (22)
 Medical 182 (69) 196 (70)
 Trauma 24 (9) 22 (8)
Diabetes mellitus 57 (22) 71 (25) 0.363
COPD 65 (25) 66 (23) 0.833
Chronic heart failure 48 (18) 43 (15) 0.431
Cirrhosis 22 (8) 16 (6) 0.298
Chronic renal failure 16 (6) 23 (8) 0.427
Immunosuppression 39 (15) 44 (16) 0.867
Study 0.828
 1 68 (26) 69 (25)
 2 61 (23) 61 (22)
 3 134 (51) 150 (53)
Table 3 Patient characteristics during ICU stay
Data are number (%), or median (IQR)
SOFA sequential organ failure assessment, MV mechanical ventilation, Pcuff cuff 
pressure, PEEP positive end expiratory pressure, HOB head of bed
Continuous control of Pcuff
Yes (n = 263) No (n = 280) p value
SOFA score at randomization 4 (1, 7) 4 (2, 6) 0.538
Subglottic secretion drainage 53 (20) 65 (23) 0.447
Antimicrobial treatment 237 (90) 260 (93) 0.321
MV duration before randomi-
zation
0 (0, 1) 0 (0, 1) 0.531
Sucralfate 42 (16) 45 (16) >0.999
Proton-pump inhibitor 182 (69) 180 (64) 0.732
H2 receptor antagonists 31 (12) 47 (17) 0.124
Reintubation 41 (15) 30 (11) 0.120
Mean Pcuff 25 (24, 26) 22 (21, 24) <0.001
Underinflation of Pcuff 2 (1) 118 (42) <0.001
% Pcuff measurements <20 
cmH2O
0 (0,0) 16 (0, 18) <0.001
Overinflation of Pcuff 8 (3) 82 (29) <0.001
Mean PEEP (cmH2O) 5 (5, 5) 5 (5, 5) 0.358
Sedation 235 (89) 253 (90) 0.806
Ramsay score 4 (3, 4) 4 (3, 4) 0.432
HOB elevation (°) 37 (30, 40) 35 (30, 40) 0.508
Paralytic agent use 22 (8) 32 (11) 0.315
Red blood cell transfusion 77 (29) 73 (26) 0.359
Enteral nutrition 178 (68) 195 (70) 0.689
Tracheostomy 49 (19) 41 (15) 0.257
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continuous control of Pcuff or to low-volume low-pres-
sure cuff use. This is the reason why these studies were 
not included in our analysis. Similarly, two other studies 
showed a beneficial effect of implementing a bundle for 
VAP prevention, including routine care for tracheal cuff 
[34, 35]. However, whether this beneficial effect is related 
to Pcuff control is unknown.
Different devices for continuous control of Pcuff
The heterogeneity between the three trials was high, prob-
ably reflecting the use of different devices for Pcuff control. 
An experimental study reported that electronic Pcuff con-
trollers with rapid pressure correction interfere with the 
self-sealing mechanism of high-volume, low-pressure 
PVC–cuffed tracheal tubes and reduce their sealing char-
acteristics [36]. Further, a recent prospective crossover 
study compared the efficiency of a pneumatic with an 
electronic device aiming at continuously controlling Pcuff 
[37]. The authors found underinflation of tracheal cuff 
to be more frequent using the electronic device than the 
pneumatic device (7 vs 0  %, respectively) and attributed 
this result to the over compensation of any elevated Pcuff.
Future studies
Future randomized controlled multicenter studies are 
required to confirm the beneficial effect of continuous 
control of Pcuff on VAP incidence, before recommend-
ing its routine use. In addition, the efficiency of different 
available devices should also be compared in critically ill 
patients.
Table 4 Microorganisms responsible for  ventilator-associ-
ated pneumonia
VAP ventilator-associated pneumonia, MDR multidrug resistant
Data are number (%)
p > 0.2 for all comparisons
Continuous control of Pcuff
Yes (n = 36) No (n = 72)
Microorganisms (n) 38 80
Polymicrobial VAP 2 (5) 8 (11)
MDR bacteria 13 (36) 30 (42)
Gram-negative 33 (92) 66 (92)
 Pseudomonas aeruginosa 5 (14) 14 (19)
 Enterobacter species 3 (8) 9 (12)
 Escherichia coli 6 (17) 5 (7)
 Citrobacter freundii 1 (3) 4 (5)
 Acinetobacter baumannii 2 (5) 5 (7)
 Haemophilus influenzae 8 (22) 8 (11)
 Stenotrophomonas maltophilia 1 (3) 4 (5)
 Klebsiella oxytoca 2 (5) 6 (8)
 Serratia species 2 (5) 7 (10)
 Others 3 (8) 4 (5)
Gram-positive 5 (14) 14 (19)
 Methicillin-resistant S. aureus 1 (3) 7 (10)
 Methicillin-sensitive S. aureus 1 (3) 3 (4)
 Streptococcus pneumoniae 1 (3) 2 (3)
 Others 2 (5) 2 (3)
Fig. 2 VAP-free survival curves for patients assigned to continuous control of cuff pressure and routine care groups. p value, and hazard ratio were 
calculated using Cox proportional hazard model stratified on trial
Table 5 Impact of  continuous control of  cuff pressure 
on secondary outcomes
Data are number (%), or median (interquartile range)
MV mechanical ventilation, VAP ventilator-associated pneumonia, ICU intensive 
care unit
Continuous control of Pcuff
Yes (n = 263) No (n = 280) p value
MV duration (day) 8 (4, 16) 8 (4, 16) 0.681
MV free days 3 (0, 6) 2 (0, 5) 0.426
ICU length of stay (day) 11 (6, 24) 12 (7, 21) 0.440
Duration of antibiotic treatment 9 (6, 15) 10 (6, 15) 0.778
ICU mortality 86 (33) 91 (32) >0.999
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Conclusions
Continuous control of Pcuff might be beneficial in reduc-
ing the incidence of VAP. However, no significant impact 
of this preventive measure was found on duration of 
mechanical ventilation, mechanical ventilation-free days, 
antimicrobial treatment, or ICU mortality. Further studies 
are required to confirm these results and to evaluate safety 
and cost-effectiveness of this preventive measure of VAP.
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